PEOPLE Edison Liu (left) will leave his position as founding executive its board of directors. McMahon currently director of the Genome Institute of Singapore to become president serves as senior vice president of R&D and and CEO of The Jackson Laboratory (Bar Harbor, ME, USA) as of head of the oncology innovative medicines January 2012. He succeeds Rick Woychik, who departs for the unit for AstraZeneca. He has held various National Institute of Environmental Health Sciences where he will roles at Pfizer, Pharmacia, Sandoz and SUGEN. serve as deputy director. Formerly scientific director of the National Shiebler and Kessel will serve the remainder Cancer Institute’s division of clinical sciences, Liu was recruited of their current terms on the board but will to run GIS in 2001. He is also a two-term president of the Human not stand for reelection at OXiGENE’s annual Genome Organization. stockholder meeting this Fall. Leo Holt, chair of The Jackson Laboratory board of trustees said, “The Jackson Laboratory is a dynamic pivot point at the intersection of mammalian and Thrasos (Montreal) has announced the appoint- human genetics. [Ed Liu’s] talents run broad and deep, and his leadership is a great ment of Andreas Orfanos as chief medical offi- addition to the team that leads the search for tomorrow’s cures.” cer. Orfanos has over 25 years of experience in strategy development and executive and opera- Adrian Adams has been appointed chairman & Manufacturers of America and as deputy tional management in the healthcare industry, and CEO, and Andrew I. Koven has been assistant for the Asia-Pacific region in the Office as a principal in his own consulting firm and as named president and chief administrative offi- of the US Trade Representative. executive vice president, strategic planning and cer of Neurologix (Fort Lee, NJ, USA). Both scientific affairs at Neurochem. Adams and Koven also join the company’s XOMA (Berkeley, CA, USA) has announced board of directors, with Adams assuming the the resignation of Steve Engle as CEO, presi- Orion Genomics (St. role of chairman. Previously, Adams served as dent and chairman of the board. John Varian, Louis) has named Steven president and CEO of Inspire Pharmaceuticals a current board member, has been appointed W. Smith vice president and Sepracor. as interim CEO. He has previously served as of bioinformatics. Smith COO and CFO of Aryx Therapeutics and brings over 20 years of Acorda Therapeutics (Hawthorne, NY, USA) CFO of Genset. A search has been initiated for experience in the biotech has named Enrique J. Carrazana as chief a permanent CEO. In addition, W. Denman and bioinformatics field, medical officer, succeeding Thomas Wessel. Van Ness, XOMA’s lead independent director, most recently as head of Carrazana has over 20 years of experience has been named chairman of the board. consulting firm Genesmith Informatics. He in the pharma industry and clinical practice. previously served as vice president of bioinfor- Most recently, he was director of the Epilepsy Five Prime Therapeutics (S. San Francisco, CA, matics at NimbleGen Systems and has worked © 2011 Nature America, Inc. All rights reserved. All rights Inc. America, Nature © 2011 Center of Excellence at the Miami Veterans’ USA) has announced the election of Peder K. at Millipore, Genetics Computer Group and the Administration Hospital and associate profes- Jensen to its board of directors. Jensen most Harvard Genome Laboratory. sor of neurology at the University of Miami recently served as corporate senior vice presi- Miller School of Medicine. Prior to this, he held dent and general manager, R&D for Japan and Nikolaj Sørensen has been named chief com- various leadership roles at Novartis, including Asia/Pacific at Schering-Plough. He currently mercial officer for Orexo (Uppsala, Sweden). He vice president, global head of the established serves on the boards of Acorda Therapeutics previously worked at Pfizer where he was direc- medicines development franchise. and BioCryst Pharmaceuticals. tor and brand team leader for the company’s leading pain treatment product in Europe and Silence Therapeutics (London) has announced Robert Lollini has been appointed as CEO and Canada, as well as head of business development the appointment of Thomas Christély as CEO. a member of the board of directors of Myrexis and director of strategic planning for Pfizer AB. Christély is a 20-year veteran of corporate and (Salt Lake City, UT, USA). He joined the com- business development and finance, having pany in February 2009 as CFO and treasurer, Marc Tessier-Lavigne has been named to the served as CFO, COO and CEO of Atugen and rising to the position of interim president and board of directors of Agios Pharmaceuticals senior vice president and CFO at OXO Chemie. CEO. Previously, he was president and CEO (Cambridge, MA, USA). He is currently presi- He currently serves as nonexecutive chairman of of Iomed. Additionally, Myrexis has named dent of The Rockefeller University in New York the supervisory board of Müller-Spreer. He will Andrea Kendell as CFO. She had served as and formerly served as executive vice president be based at Silence’s facility in Berlin. vice president, finance and human resources for research and CSO at Genentech. since June 2010. The Biotechnology Industry Organization Immunovaccine (Halifax, Nova Scotia, (Washington) has selected Joseph Damond as OXiGENE (S. San Francisco, CA, USA) Canada) has appointed John J. Trizzino as senior vice president, international affairs. He has announced the appointment of Gerald CEO and a member of the board. He joins previously served as deputy vice president, inter- McMahon and the impending retirements Immunovaccine from Novavax, where he national affairs at the Pharmaceutical Research of William Shiebler and Mark Kessel from served as senior vice president. 950 VOLUME 29 NUMBER 10 OCTOBER 2011 NATURE BIOTECHNOLOGY.